InvestWiser

Elicera Therapeutics AB

ELICNasdaq StockholmHealthcareMarket value 163 m SEK
2.44SEK −1.2%
last day · Price as of 19 November 2026

The answer first

Does Elicera Therapeutics beat the market?

No, Elicera Therapeutics has not beaten the market over the last year.

Elicera Therapeutics−53.6%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 15% of Nordic stocks

    • Quality67
    • Value7
    • Trend21

    No. 149 of 195 in healthcare

Max for seven days

Follow Elicera Therapeutics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Elicera Therapeutics

From today, at a price of 2.44 SEK. Write why you follow Elicera Therapeutics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Elicera Therapeutics

Your first answer is free, no account needed.

Do you own Elicera Therapeutics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Elicera Therapeutics and a few more. Free, no card.

Past year against the exchange and Super Stock
Elicera Therapeutics−53.6%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Elicera Therapeutics has fallen 53.6% over the past year, including dividends.
  • Overall, Elicera Therapeutics ranks better than 15% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 90.0%. The price is 71.6% below its peak now.

What do analysts think of Elicera Therapeutics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

15

Quality, value and trend together. Better than 15% of Nordic stocks.

No. 149 of 195 in healthcare

Quality67
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 92 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity–
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−32.0%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value7
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 153 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity2.2
  • P/SPrice divided by salesnegative earnings
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend21
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 124 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−6.0%
  • 6 months−18.8%
  • 9 months−56.8%
  • 12 months−53.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−15.4%
3 years, per year
−20.2%
5 years, per year
−17.4%
Year to date
−53.3%
Largest fall, 3 years
−90.0%
From a peak to the bottom
From the peak now
−71.6%
How far the price is from the peak
Volatility, 1 year
75.1%
How much the price swings over a year
Beta, 1 year
1.04
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Elicera Therapeutics

One fund we follow owns Elicera Therapeutics. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Elicera Therapeutics

Elicera Therapeutics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 3 employees.

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors.

See the full analysis of Elicera Therapeutics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market